Skip to main content
PIRAMAL PHARMA LIMITED logo

PIRAMAL PHARMA LIMITED — Investor Relations & Filings

Ticker · PPLPHARMA ISIN · INE0DK501011 LEI · 3358006D6AL7PZ4U9T51 BSE.NS Manufacturing
Open in API
Filings indexed 365 across all filing types
Latest filing 2025-04-29 Regulatory Filings
Country IN India
Listing BSE.NS PPLPHARMA

About PIRAMAL PHARMA LIMITED

https://www.piramalpharma.com/

Piramal Pharma Limited provides a broad range of products and services across the drug lifecycle through three main business segments: Piramal Pharma Solutions, Piramal Critical Care, and Consumer Healthcare. Piramal Pharma Solutions operates as an integrated Contract Development and Manufacturing Organization (CDMO), offering end-to-end services from drug discovery and development to commercial manufacturing of APIs and formulations. Piramal Critical Care focuses on complex hospital generics, holding a significant global market share in inhalation anesthetics, including Sevoflurane and Isoflurane, as well as injectable anesthesia and pain management therapies. The Consumer Healthcare division manages a diverse portfolio of over-the-counter brands such as Saridon, Lacto Calamine, and Tetmosol. The company leverages an extensive global manufacturing network to deliver specialized healthcare solutions worldwide.

Recent filings

Filing Released Lang Actions
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-04-29 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a notification about an upcoming conference call scheduled for May 15, 2025, to discuss the Q4 and FY2025 financial results of Piramal Pharma Limited. It includes dial-in details and registration information for investors and analysts. The text does not contain any actual financial data, analysis, or detailed discussion of results, but rather serves as an announcement of the event where such information will be discussed. The document length is 3629 characters, which is relatively short and consistent with an announcement rather than a full report or transcript. Therefore, this document is best classified as a Call Transcript announcement or invitation, but since it is only an intimation of the conference call and not the transcript itself, it fits the category of Regulatory Filings (RNS) as a general regulatory announcement under SEBI Listing Regulations.
2025-04-29 English
Acquisition
Capital/Financing Update Classification · 95% confidence The document is a disclosure under Regulation 30 of the SEBI Listing Regulations, which pertains to material events or information that a listed company must disclose to stock exchanges. The content describes a transaction involving subscription to preference shares and loan conversion within the company's subsidiaries. It is an announcement of a capital/financing activity rather than a full financial report or earnings release. The document length is short (2824 characters) and it does not contain financial statements or detailed financial analysis. Therefore, it is best classified as a Capital/Financing Update (CAP).
2025-04-23 English
Commencement of commercial production/operations
Regulatory Filings Classification · 95% confidence The document is a short disclosure letter addressed to stock exchanges under Regulation 30 of the SEBI Listing Regulations, 2015. It announces the commencement of commercial production of a product at a company facility. The document is brief (1589 characters) and serves as an announcement of a material event rather than a detailed report or financial statement. It does not contain financial data, management discussion, or detailed analysis. It is not a report publication announcement since it does not mention any report being attached or published. The content fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about a material event under listing obligations.
2025-04-01 English
Shareholders meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed communication regarding the results of a postal ballot and e-voting process for the appointment of a non-executive, non-independent director at Piramal Pharma Limited. It includes the Scrutinizer's Report pursuant to Sections 108 and 110 of the Companies Act, 2013, and Regulation 44 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The document contains voting results, percentages, and certification by the scrutinizer, indicating it is an official declaration of voting results from a shareholder vote. There is no financial data or management discussion, nor is it an announcement of a report publication. The content fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-03-21 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a formal announcement addressed to stock exchanges (BSE and NSE) informing about the receipt of Market Authorisation from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for a new pediatric drug formulation. It includes a press release about the approval and commercialization rights. The content is focused on a regulatory approval milestone and commercial update rather than financial results, management changes, or detailed financial data. The document is relatively short (5957 characters) and serves as a notification to the market rather than a detailed report or presentation. There is no financial data, earnings information, or management discussion. Therefore, it fits best as a Regulatory Filing (RNS), which is a general regulatory announcement category for filings that do not fit other specific categories.
2025-03-20 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.